Skip to content

Drug interactions

Eliglustat + Sorafenib

Severity: Major

Eliglustat and Sorafenib: major interaction.

Last updated

For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.

Summary

Both drugs can prolong the PR, QRS and QT intervals, so combining them may increase the risk of ventricular arrhythmias. Eliglustat labeling warns against use with Class IA and III antiarrhythmics and cautions about other QT-prolonging drugs.

What this interaction means in plain words

Eliglustat and Sorafenib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.

Eliglustat belongs to Miscellaneous; Sorafenib belongs to Oncology.

Evidence level: Low

Why it happens

Additive pharmacodynamic QT prolongation.

What to do

Avoid the combination if possible. If it is used, obtain a baseline ECG, monitor the QTc and correct electrolyte abnormalities.

What to ask your pharmacist

  • Does the benefit of taking both outweigh the risk in my case?
  • Do I need any blood test, ECG or other check while on both?
  • What early warning signs should I watch for, and what should I do if they appear?

Bring a full list of your medicines, including over-the-counter products, supplements and herbal remedies, to every pharmacy visit.

Pro+ members

Unlock the full page

Create an account and start a Pro+ trial to unlock the full management advice for Eliglustat and Sorafenib, the additional notes, the evidence detail and the whole-prescription interaction checker.

  • Full clinical management advice
  • Additional notes
  • Evidence detail
  • Interaction checker for a whole prescription

Try Pro+ free for 14 days on the web. No card needed.

Frequently asked questions

Can I take Eliglustat with Sorafenib?

MediHelp rates the interaction as major. Eliglustat and Sorafenib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Both drugs can prolong the PR, QRS and QT intervals, so combining them may increase the risk of ventricular arrhythmias. Eliglustat labeling warns against use with Class IA and III antiarrhythmics and cautions about other QT-prolonging drugs.

How serious is the interaction between Eliglustat and Sorafenib?

MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid the combination if possible. If it is used, obtain a baseline ECG, monitor the QTc and correct electrolyte abnormalities.

What other medicines interact with Sorafenib?

MediHelp also lists interactions of Sorafenib with, for example, Adagrasib, Amiodarone, Amisulpride. The full list is on the Sorafenib page.

Full monographs, dosing and an interaction checker in the MediHelp app

Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.

Browse A–Z · Drug interactions

Get the app Sign in